Home › Funds › Fidelity › Select Biotechnology Portfolio
Fund family: Fidelity · Filed by FIDELITY SELECT PORTFOLIOS (CIK 320351) · SEC series S000007486
Ticker: FBIOX (C000020460)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,066 with, 6 against, 4 abstentions (not counted as with management); 2 items carried no recommendation. Shareholder proposals: 2 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Fidelity | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 86.4% | 1,008 | 94.1% | 974,562 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 6.8% | 11,096 |
Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Fidelity funds on 61 items (6.1% of the 998 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Perspective Therapeutics, Inc. | 2026-05-27 | Election of Directors: Robert Froman Williamson, III | For | WITHHOLD — 10 of 10 Fidelity funds | For | Passed (calculated), 87.9% support |
| ARS Pharmaceuticals, Inc. | 2026-06-24 | To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Laura Shawver, Ph.D. | Withhold | FOR — 13 of 14 Fidelity funds | Against | Elected, 68.4% support |
| BioCryst Pharmaceuticals, Inc. | 2026-06-11 | To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan. | Against | FOR — 16 of 18 Fidelity funds | Against | Approved, 65.4% support |
| Ultragenyx Pharmaceutical Inc. | 2026-05-14 | Nominees: Daniel G. Welch | Withhold | FOR — 16 of 18 Fidelity funds | Against | Passed (calculated), 90.1% support |
| Ultragenyx Pharmaceutical Inc. | 2026-05-14 | Nominees: Emil D. Kakkis, M.D., Ph.D. | Withhold | FOR — 16 of 18 Fidelity funds | Against | Passed (calculated), 98.6% support |
| Ultragenyx Pharmaceutical Inc. | 2026-05-14 | Nominees: Shehnaaz Suliman, M.D. | Withhold | FOR — 16 of 18 Fidelity funds | Against | Passed (calculated), 89.4% support |
| Ultragenyx Pharmaceutical Inc. | 2026-05-14 | Approval of the Third Amended and Restated 2023 Incentive Plan. | Against | FOR — 15 of 17 Fidelity funds | Against | Approved, 68.9% support |
| ARS Pharmaceuticals, Inc. | 2026-06-24 | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement. | For | AGAINST — 15 of 17 Fidelity funds | For | Approved, 87.6% support |
| Inhibikase Therapeutics, Inc. | 2026-06-26 | to elect two Class III directors, to the Board of Directors, each to serve until the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal: Arvind Kush | Withhold | FOR — 7 of 7 Fidelity funds | Against | Elected, 84.6% support |
| TG Therapeutics, Inc. | 2026-06-11 | Election of Directors: Daniel Hume | Withhold | FOR — 14 of 16 Fidelity funds | Against | Passed (calculated), 78.6% support |
| TG Therapeutics, Inc. | 2026-06-11 | Election of Directors: Laurence Charney | Withhold | FOR — 14 of 16 Fidelity funds | Against | Passed (calculated), 83.7% support |
| TG Therapeutics, Inc. | 2026-06-11 | Election of Directors: Yann Echelard | Withhold | FOR — 14 of 16 Fidelity funds | Against | Passed (calculated), 78.7% support |
| Corcept Therapeutics Incorporated | 2026-05-21 | To approve an amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan to increase the number of shares available thereunder and clarify certain other language in the plan. | Against | FOR — 20 of 25 Fidelity funds | Against | Approved, 69.0% support |
| Corcept Therapeutics Incorporated | 2026-05-21 | Election of Directors: David L. Mahoney | For | WITHHOLD — 19 of 24 Fidelity funds | For | Elected, 66.1% support |
| Allogene Therapeutics, Inc. | 2026-06-18 | Election of Directors: Owen Witte, M.D. | For | WITHHOLD — 12 of 14 Fidelity funds | For | Elected, 82.9% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Laura Brege | Withhold | FOR — 14 of 17 Fidelity funds | Against | Elected, 95.8% support |
| Ionis Pharmaceuticals, Inc. | 2026-06-04 | To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares. | Against | FOR — 25 of 34 Fidelity funds | Against | Approved, 77.0% support |
| BioCryst Pharmaceuticals, Inc. | 2026-06-11 | To hold a non-binding, advisory vote regarding executive compensation. | For | AGAINST — 15 of 19 Fidelity funds | For | Approved, 68.9% support |
| Prothena Corporation plc | 2026-05-14 | To elect, by separate resolutions, two directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2029, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Dennis J. Selkoe | Against | FOR — 12 of 15 Fidelity funds | Against | Elected, 72.8% support |
| Prothena Corporation plc | 2026-05-14 | To elect, by separate resolutions, two directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2029, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Shane M. Cooke | Against | FOR — 12 of 15 Fidelity funds | Against | Elected, 65.6% support |
| TG Therapeutics, Inc. | 2026-06-11 | Election of Directors: Sagar Lonial, MD | Withhold | FOR — 13 of 17 Fidelity funds | Against | Passed (calculated), 54.9% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D. | Withhold | FOR — 13 of 17 Fidelity funds | Against | Elected, 70.3% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Jonathan Root, M.D. | Withhold | FOR — 13 of 17 Fidelity funds | Against | Elected, 65.0% support |
| Capricor Therapeutics, Inc. | 2026-06-04 | ELECTION OF DIRECTORS: Frank Litvack | Withhold | FOR — 13 of 17 Fidelity funds | Against | Passed (calculated), 68.6% support |
| Cartesian Therapeutics, Inc. | 2026-06-12 | Election of Directors: Timothy A. Springer, Ph.D. | Withhold | FOR — 7 of 8 Fidelity funds | Against | Elected, 94.1% support |
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Sana Biotechnology, Inc. | 2026-06-04 | To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Hans E. Bishop | Withhold | FOR — 13 of 17 Fidelity funds | Against | — |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Conduct an advisory vote on the compensation of our named executive officers. | Against | FOR — 14 of 19 Fidelity funds | Against | Approved, 96.1% support |
| Tectonic Therapeutic, Inc. | 2026-06-08 | Election of Directors: Timothy A. Springer, Ph.D. | Withhold | FOR — 12 of 16 Fidelity funds | Against | Passed (calculated), 79.5% support |
| Forte Biosciences, Inc. | 2026-05-29 | The approval of the Company's Amended and Restated 2021 Equity Incentive Plan. | Against | FOR — 4 of 4 Fidelity funds | Against | Approved, 74.9% support |
| vTv Therapeutics Inc. | 2026-06-26 | To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Anne M. Phillips | Withhold | FOR — 4 of 4 Fidelity funds | Against | — |
| vTv Therapeutics Inc. | 2026-06-26 | To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Daniel K. Spiegelman | Withhold | FOR — 4 of 4 Fidelity funds | Against | — |
| vTv Therapeutics Inc. | 2026-06-26 | To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Fahed Al Marzooqi | Withhold | FOR — 4 of 4 Fidelity funds | Against | — |
| vTv Therapeutics Inc. | 2026-06-26 | To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Paul Sekhri | Withhold | FOR — 4 of 4 Fidelity funds | Against | — |
| vTv Therapeutics Inc. | 2026-06-26 | To elect the seven director nominees named in the Proxy Statement to serve until our next annual meeting or until their successors have been duly elected and qualified: Richard S. Nelson | Withhold | FOR — 4 of 4 Fidelity funds | Against | — |
| Roivant Sciences Ltd. | 2025-09-10 | To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Keith Manchester | Withhold | FOR — 16 of 24 Fidelity funds | Against | Elected, 70.6% support |
| Roivant Sciences Ltd. | 2025-09-10 | To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Matthew Gline | Withhold | FOR — 16 of 24 Fidelity funds | Against | Elected, 73.6% support |
| Roivant Sciences Ltd. | 2025-09-10 | To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Melissa Epperly | Withhold | FOR — 16 of 24 Fidelity funds | Against | Elected, 73.5% support |
| Nuvation Bio Inc. | 2026-05-21 | Election of Directors: Robert Bazemore | For | WITHHOLD — 12 of 17 Fidelity funds | For | Elected, 84.0% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Kenneth A. Clark | Withhold | FOR — 15 of 23 Fidelity funds | Against | Passed (calculated), 96.1% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Mahkam Zanganeh | Withhold | FOR — 15 of 23 Fidelity funds | Against | Passed (calculated), 98.5% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Manmeet S. Soni | Withhold | FOR — 15 of 23 Fidelity funds | Against | Passed (calculated), 98.4% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Robert W. Duggan | Withhold | FOR — 15 of 23 Fidelity funds | Against | Passed (calculated), 98.3% support |
| Summit Therapeutics Inc. | 2026-06-10 | ELECTION OF DIRECTORS: Yu (Michelle) Xia | Withhold | FOR — 15 of 23 Fidelity funds | Against | Passed (calculated), 98.3% support |
| Summit Therapeutics Inc. | 2026-06-10 | Approval, by a non-binding advisory vote, of the compensation of our named executive officers. | For | AGAINST — 17 of 27 Fidelity funds | For | Passed (calculated), 96.2% support |
| Atea Pharmaceuticals, Inc. | 2026-06-18 | Election of Class III Directors: Jerome Adams, MD, MPH | Withhold | FOR — 12 of 18 Fidelity funds | Against | Passed (calculated), 56.4% support |
| Arrowhead Pharmaceuticals, Inc. | 2026-03-19 | Election of Directors: Hongbo Lu | Against | FOR — 14 of 22 Fidelity funds | Against | — |
| Arrowhead Pharmaceuticals, Inc. | 2026-03-19 | Election of Directors: William Waddill | Against | FOR — 14 of 22 Fidelity funds | Against | Passed (calculated), 90.3% support |
| Palvella Therapeutics, Inc. | 2026-06-10 | Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. Davis | Withhold | FOR — 9 of 13 Fidelity funds | Against | Passed (calculated), 81.8% support |
| Rezolute, Inc. | 2025-11-19 | To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Erik Harris | Withhold | FOR — 12 of 19 Fidelity funds | Against | Passed (calculated), 81.2% support |
| Rezolute, Inc. | 2025-11-19 | To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Nerissa Kreher | Withhold | FOR — 12 of 19 Fidelity funds | Against | Passed (calculated), 76.6% support |
| Foghorn Therapeutics Inc. | 2026-06-24 | Elect Class III directors each for a three-year term: Douglas Cole, M.D. | Against | FOR — 7 of 10 Fidelity funds | Against | Elected, 76.2% support |
| Arrowhead Pharmaceuticals, Inc. | 2026-03-19 | Election of Directors: Michael S. Perry | Against | FOR — 13 of 22 Fidelity funds | Against | — |
| uniQure N.V. | 2026-06-10 | Resolution to adopt the amendment to the Articles of Association to reflect Dutch large company regime. | For | AGAINST — 10 of 16 Fidelity funds | For | Approved, 74.5% support |
| Forte Biosciences, Inc. | 2026-05-29 | The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote"). | For | AGAINST — 4 of 5 Fidelity funds | For | Approved, 76.3% support |
| Nurix Therapeutics, Inc. | 2026-05-15 | Election of Class III Directors: Arthur T. Sands, M.D., Ph.D. | Withhold | FOR — 13 of 24 Fidelity funds | Against | Elected, 79.6% support |
| Nurix Therapeutics, Inc. | 2026-05-15 | Election of Class III Directors: Paul M. Silva | Withhold | FOR — 13 of 24 Fidelity funds | Against | Elected, 74.2% support |
| Stoke Therapeutics, Inc. | 2026-06-03 | Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne Smith | Withhold | FOR — 14 of 27 Fidelity funds | Against | Passed (calculated), 86.9% support |
| Biomea Fusion, Inc. | 2026-06-10 | The election of Rainer (Ramses) Erdtmann and Eric Aguiar, M.D., as Class II Directors, to serve for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029: Rainer (Ramses) Erdtmann | Withhold | FOR — 4 of 7 Fidelity funds | Against | — |
| CAMP4 Therapeutics Corporation | 2026-06-10 | Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Murray Stewart, DM FRCP | Against | FOR — 4 of 7 Fidelity funds | Against | — |
| CAMP4 Therapeutics Corporation | 2026-06-10 | Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Richard Young, PhD | Against | FOR — 4 of 7 Fidelity funds | Against | — |
| CAMP4 Therapeutics Corporation | 2026-06-10 | Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Steven Holtzman | Against | FOR — 4 of 7 Fidelity funds | Against | — |
Download all 61 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 72.1% of this fund’s 1,076 such votes could be given a sector; the other 300 (27.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 776 | 6 | 0.8% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 577 | 0 |
| Audit-related | 159 | 0 |
| Say-on-Pay | 138 | 0 |
| Compensation | 86 | 0 |
| Capital Structure | 73 | 0 |
| Corporate Governance | 63 | 4 |
| Extraordinary Transactions | 2 | 0 |
| Other Social Issues | 2 | 1 |
| Shareholder Rights and Defenses | 2 | 0 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| AbbVie Inc. | May 8, 2026 | $754M | 8 | 1 |
| Amgen Inc. | May 19, 2026 | $530M | 15 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $527M | 15 | 3 |
| Krystal Biotech, Inc. | May 15, 2026 | $520M | 5 | 0 |
| argenx SE | November 18, 2025 | $157M | 1 | 0 |
| Moderna, Inc. | November 12, 2025 | $120M | 2 | 0 |
| Praxis Precision Medicines, Inc. | June 10, 2026 | $120M | 5 | 0 |
| Insmed Incorporated | May 13, 2026 | $114M | 4 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
1,103 ballot items at 159 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Select Biotechnology Portfolio (FBIOX) voted at 159 shareholder meetings of 153 companies, on 1,103 ballot items in all. Where management made a recommendation, the fund followed it on 99.1% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 8 shareholder proposals. It voted FOR the board's own proposals less often than Fidelity's funds as a whole (86.4% against 94.1%). It voted differently from most Fidelity funds on 61 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.